

1 ***Monodelphis domestica* as a fetal intra-cerebral inoculation model for Zika virus**
2 **pathogenesis**

3 Short Title: Fetal intra-cerebral model for Zika virus pathogenesis

4 **John M. Thomas III^{1,2,5*}, Juan Garcia², Matthew Terry², Ileana Lozano², Susan M.**
5 **Mahaney^{3,4,5}, Oscar Quintanilla², Dionn Carlo-Silva², Marisol Morales², and John L.**
6 **VandeBerg^{1,3,4,5*}**

7

8

9 ¹Center for Vector Borne Disease, The University of Texas Rio Grande Valley,
10 Edinburg/Harlingen/Brownsville, Texas, United States of America

11 ²Department of Biology, The University of Texas Rio Grande Valley,
12 Edinburg/Harlingen/Brownsville, Texas, United States of America

13 ³South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley,
14 Edinburg/Harlingen/Brownsville, Texas, United States of America

15 ⁴Department of Human Genetics, The University of Texas Rio Grande Valley,
16 Edinburg/Harlingen/Brownsville, Texas, United States of America

17 ⁵School of Medicine, The University of Texas Rio Grande Valley,
18 Edinburg/Harlingen/Brownsville, Texas, United States of America

19

20 *Corresponding authors

21 Email: john.thomas@utrgv.edu (JMT), john.vandenberg@utrgv.edu (JLV)

22

23

24

25

26

27

28

29

30

31

32

33 **ABSTRACT**

34 *Monodelphis domestica*, also known as the laboratory opossum, is a marsupial native to South
35 America. At birth, these animals are developmentally equivalent to human embryos at
36 approximately 5 weeks of gestation which, when coupled with other characteristics including the
37 size of the animals, the development of a robust immune system during juvenile development,
38 and the relative ease of experimental manipulation, have made *M. domestica* a valuable model in
39 many areas of biomedical research. However, their suitability as models for infectious diseases,
40 especially diseases caused by viruses such as Zika virus (ZIKV), is currently unknown. Here, we
41 describe the replicative effects of ZIKV using a fetal intra-cerebral model of inoculation. Using
42 immunohistochemistry and in situ hybridization, we found that opossum embryos and fetuses are
43 susceptible to infection by ZIKV administered intra-cerebrally, that the infection persists long
44 term, and that the infection and viral replication consistently results in neural pathology and may
45 occasionally result in global growth restriction. These results demonstrate the utility of *M.*
46 *domestica* as a new animal model for investigating ZIKV infection *in vivo*. This new model will
47 facilitate further inquiry into viral pathogenesis, particularly for those viruses that are
48 neurotropic, that may require a host with the ability to support sustained viral infection, and/or
49 that may require intra-cerebral inoculations of large numbers of embryos or fetuses.

50 **AUTHOR SUMMARY**

51 Here we show that the laboratory opossum (*Monodelphis domestica*) is a valuable new model for
52 studying Zika virus pathogenesis. Newborns are at the developmental stage of 5-week human
53 embryos. Zika virus inoculated on a single occasion into the brains of pups at the human
54 developmental stages of 8-20 weeks post conception replicated in neuronal cells and persisted as
55 a chronic infection until the experimental endpoint at 74-days post infection. In addition, we

56 observed global growth restriction in one of 16 inoculated animals; global growth restriction has
57 been observed in humans and other animal models infected with Zika virus. The results illustrate
58 great potential for this new animal model for high throughput research on the neurological
59 effects of Zika virus infection of embryos and fetuses.

60 INTRODUCTION

61 Zika virus (ZIKV) is a small, enveloped positive-sense RNA virus from the family
62 *Flaviviridae*. Typically transmitted in a zoonotic cycle that alternates between a vertebrate host
63 and an invertebrate vector, ZIKV gained notoriety following the 2015 outbreak in Brazil, which
64 saw a dramatic increase in the number of neurological abnormalities in infants born to ZIKV-
65 infected mothers [1]. Significant increases in Guillain-Barre syndrome and microcephaly during
66 this outbreak were also observed when compared to previous years [2], perhaps fulfilling the
67 theory posited by Hayes when he declared ZIKV to be neurovirulent [3].

68 Following the initial isolation of ZIKV from the upper canopy of the Ziika Forest in
69 Uganda in 1947 [4], little research into the neuropathology of ZIKV had been carried out prior to
70 the Brazilian epidemic. It is estimated that more than 400 babies were born with microcephaly
71 and other brain abnormalities to ZIKV-infected pregnant women during this outbreak [5] and,
72 subsequently, analysis of fetal tissue collected from ZIKV-infected infants supports a causal
73 relationship between ZIKV and neurological abnormalities, as ZIKV has been detected in brain
74 tissue of microcephalic fetuses, as well as in amniotic fluid of pregnant women [6, 7, 8]. The
75 dramatic increase in the incidence of microcephaly and other fetal abnormalities from the
76 Brazilian outbreak has spurred the development of animal models of infection in order to study
77 the effects of ZIKV replication *in vivo*, with a particular focus on the neurotropism of ZIKV. To

78 date, the principal animal models for assessing ZIKV pathology have been nonhuman primates
79 (NHPs) and transgenic mice; limited studies also have been conducted with chicken embryos [9].

80 The NHP model is the most relevant in terms of reproducing the pathology *in vivo*
81 compared to what is known about ZIKV-induced pathologies in humans [10, 11, 12, 13].
82 Macaques have been the NHP model used most frequently, and several studies have
83 demonstrated the advantages of the NHP model by comparison with the mouse model, including
84 similarities to human gestation, ease of studying placental transmission, and robust immune
85 responses as expected in an immuno-competent animal model [10, 14]. In a fetal macaque
86 model, ZIKV elicited severe pathological effects on the central nervous system (CNS) including
87 damage to the axonal and ependymal area, gliosis, and hypoplasia of the cerebral white matter
88 [13]. Other studies using NHPs have shown high viral loads in the sex organs and consistent
89 viral shedding in the oral mucosa, further suggesting that NHPs may be uniquely suited to
90 addressing many questions pertaining to ZIKV pathogenesis *in vivo* [10, 15]. However, the cost
91 associated with the use and maintenance of NHPs precludes large-scale experimentation. This
92 limitation, together with the long duration of time required to investigate effects of ZIKV
93 infection during gestation on development during infancy, adolescence, and into adulthood and
94 old age in NHPs, suggests that additional animal models are required.

95 Studies conducted with immune-deficient murine models have demonstrated the ability
96 of ZIKV to replicate in neuronal and ocular tissue [16], to delay development and whole-body
97 growth [17], to reduce cortical thickness and cell numbers [17], and to elicit apoptosis in ZIKV-
98 infected neurons [18]. Many of the immune-deficient murine models are based on the abatement
99 of type I interferon responses (A129 mice) or types I and II interferon (AG129 mice) [19]. These
100 animals are highly susceptible to ZIKV infection, maintain a high viral load in the CNS, and

101 demonstrate the ability of ZIKV to infect cells associated with the testes, an observation that is
102 consistent with the findings of sexual transmission of ZIKV from males to females in humans
103 [20, 21]. The transgenic murine models have generated useful data regarding ZIKV
104 pathogenesis; however, because these animals are deficient in cell-mediated immune responses
105 that are often the most effective defense against intracellular pathogens [22], data from
106 transgenic murine models may not be fully representative of the pathology observed in humans.

107 Other studies have used sub-cutaneous ZIKV infection of immunocompetent 1-day-old
108 C57BL/6 pups (immunocompetent to the limited extent that 1-day-old mouse pups have begun to
109 develop their immune system), which resulted in the development of major brain abnormalities
110 including neuronal cell death, gliosis, and axonal rarefaction [23], all of which are representative
111 of ZIKV replication in human brain tissue [2, 24, 25,]. From a developmental perspective,
112 however, a 1-day-old mouse pup is approximately equivalent to a human fetus at 19-weeks of
113 gestation [26] and, as such, is not suitable for modeling the effects of ZIKV infection of human
114 embryonic and earlier fetal stages. Moreover, C57BL/6 pups inoculated at 3 or 10 days of age
115 did not develop any signs of disease, so the neonatal mouse model is limited to a single stage of
116 fetal development.

117 In an effort to model ZIKV infection of those stages of human development, Shao et al.
118 [27] performed intra-cerebral inoculations of e14.5-day mouse embryos with ZIKV and allowed
119 them to develop. An e14.5 mouse embryo is developmentally equivalent to a human embryo at
120 7-8 weeks post-conception [26]. Massive neuronal death occurs in the inoculated embryos and,
121 although it is possible for some of them to survive to birth, the oldest animal reported was 3 days
122 old, suggesting that the infection is lethal within days of birth. Because of the time and effort
123 required for inoculating mouse embryos, this model is not practical for high throughput

124 experiments that are required for modeling the various potential outcomes of human embryo
125 infection with ZIKV. Moreover, since the infection is lethal in this model, it is not possible to
126 use it to investigate long-term sequelae of ZIKV infection at the embryonic stage.

127 Because all of the existing animal models of ZIKV-induced pathogenesis have significant
128 limitations, we explored the potential of a marsupial model to circumvent those limitations. The
129 gray short-tailed opossum, *Monodelphis domestica*, is native to Brazil and surrounding countries.
130 The laboratory genetic stocks and inbred strains of this species are collectively referred to as the
131 laboratory opossum [28]. Laboratory opossums are widely used as models in many fields of
132 biomedical research [29], and they possess some characteristics that render this model suitable,
133 and in some respects, unique, for studying the pathogenesis of ZIKV *in vivo*. First, the animals
134 are small (80-140g as adults), but several times the size of a mouse, facilitating some
135 experimental procedures by comparison with mice, such as serial collections of substantial
136 quantities of blood. Second, they are highly fecund, and easy to manipulate; and they can be
137 produced and maintained cost-effectively. Third, at birth, *M. domestica* are developmentally
138 equivalent to a human embryo at approximately 5 weeks of gestation [26], and they complete
139 embryonic and most of fetal development while attached to the mother's nipples over a 2-week
140 period [30]. Fourth, female *M. domestica* do not have pouches, so the pups can easily be
141 experimentally manipulated while they are attached to the nipples, and they have a high rate of
142 survival post-manipulation. Fifth, while the immune system is undeveloped at birth, *M.*
143 *domestica* develop a fully intact immune system as they develop beyond the fetal stage. Last, as
144 is also true for the immune-deficient murine models, but not for the in utero murine model or the
145 NHP model, large numbers of *M. domestica* can be used economically, enabling robust statistical

146 analysis for between-group comparisons, as well as robust assessment of within-group variations
147 in outcome of ZIKV infection.

148 We emphasize the importance of being able to assess within-group variation in large
149 numbers of animals inoculated with ZIKV, for the purpose of modeling the major variations in
150 pathological outcome of human infection with ZIKV. For example: 1) growth retardation and
151 microcephaly are uncommon outcomes of ZIKV infection of human embryos and fetuses [24];
152 eye pathologies occur in only a minority of children who were infected in utero and in only a
153 small proportion of children and adults who become infected with ZIKV [6, 31]; Guillain-Barre
154 syndrome is caused by ZIKV infection in only a minority of people [32].

155 The purpose of this study was to assess the utility of *M. domestica* as an intra-cerebral
156 model for ZIKV neuropathogenesis by determining if ZIKV can replicate and persist in the
157 brains of young pups and, if so, to determine the nature and extent of the neuropathological
158 consequences by comparison with those observed in humans and other animal models.

159 We point out that the experiment reported here is not intended to model the complex
160 biological processes that lead to infection of brains of human embryos and fetuses with ZIKV,
161 typically beginning with the bite of a mosquito, replication in the mother, trans-placental transfer
162 to the embryo or fetus, replication in the embryo or fetus, followed by entry into the brain and
163 replication in the brain. Rather, our model obviates all of the variables and mechanistic
164 complexities that exist between the time of initial infection of the mother and entry of the virus
165 into the brain of the embryo or fetus. Via the use of this unique model, we can conduct high
166 throughput experiments to investigate short-term and long-term pathological effects of variation
167 in the number of PFU that enter the brain, the exact developmental time point at which they enter

168 the brain, and the genetic make-up of different ZIKV strains, in the absence of the many
169 confounding variables that exist in models of trans-placental infection of embryos and fetuses.

170 **METHODS**

171 **Animals**

172 The laboratory opossums used in this study were produced in the breeding colony maintained at
173 The University of Texas Rio Grande Valley and maintained under standard conditions [28].

174 **Ethics Statement**

175 All animal work described herein was subject to review and approval by the UTRGV
176 Institutional Animal Care and Use Committee (IACUC), as well as oversight provided by the
177 UTRGV Department of Laboratory Animal Resources (LAR). LAR maintains compliance with
178 the National Institutes of Health Office of Laboratory Animal Welfare (NIH OLAW) Public
179 Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals; PHS Assurance
180 number A4730-01, and the United States Department of Agriculture (USDA); USDA Assurance
181 number 74-R-0216. The animal protocol for this work was approved, and conducted under the
182 IACUC protocol of Dr. John Thomas (#2016-005-IACUC).

183 **Susceptibility of *M. domestica* pups to ZIKV infection**

184 In the first experiment, *M. domestica* pups were inoculated with 5,000 PFU of ZIKV
185 PRVABC59 intra-cerebrally. Two litters at 2 and 3 days of age, respectively, were used,
186 hereafter referred to as Group 1 and Group 2. Each group contained three animals. At 19 days
187 post-inoculation, the animals were euthanized, and whole brains were collected, weighed, and
188 homogenized for virus titration.

189 **Developmental effects of intracerebral inoculation**

190 Following the initial confirmation that *M. domestica* pups could be infected with ZIKV via the
191 intra-cerebral route, in the second experiment we examined the effects of ZIKV infection on
192 postnatal development in the laboratory opossum model. *M. domestica* pups ranging in age from
193 4-20 days (equivalent in human development to 8-20 weeks post conception) were inoculated
194 intra-cerebrally with 5,000 PFU of ZIKV as described above. Control animals, ranging in age
195 from 2-9 days, were inoculated with PBS. Seventy-two days after the inoculations, the animals
196 were euthanized, weighed, and measured; and brain tissue was collected for analysis by
197 immunohistochemistry and in situ hybridization.

198 **Cells and viruses**

199 ZIKV isolate PRVABC59 (a gift from Dr. Kenneth Plante at the WRCEVA repository at
200 UTMB) was used for the inoculations. Vero cells (CCL-81; ATCC, USA) were used for virus
201 titration, and C6/36 cells (CRL-1660; ATCC, USA) derived from *Aedes albopictus* were used to
202 amplify lyophilized virus for scale-up. Virus generated from the initial reconstituted lyophilized
203 stock was passaged once in C6/36 cells, and the resulting supernatant was clarified and purified
204 over a sucrose cushion. Virus supernatants were quantified in duplicate by plaque assay, as
205 described previously [33]. Aliquots were stored at -80°C for further use.

206 **Tissue fixation and sectioning**

207 Dissected tissue was fixed in sterile PBS (Gibco, USA) + 4% formaldehyde solution and stored
208 at room temperature. Fixative was then cleared from tissue by performing three quick washes in
209 sterile PBS followed by three 10-min washes in sterile PBS. Next, the tissue was washed 1X for
210 5 min in a 25% methanol:PBS solution; washed 1X for 5 min in 50 % methanol:PBS solution;

211 and finally washed 3X for 5 min in 100% methanol. Tissue was stored at -20°C until needed.
212 Tissue was rehydrated by washing 1X for 5 min in 50% sterile methanol:PBS; washed 1X for 5
213 min in 75% methanol:PBS, and then washed 3X for 5 min in sterile PBS. Tissue was incubated
214 for 30 min in 33% OCT mounting media: sterile PBS, 30 min in 66% OCT: sterile PBS, 1-4
215 hours in 100% OCT. Tissue was mounted in OCT and cooled to -20°C for sectioning by a
216 cryostat (Leica Biosystems, USA). Sections of 10 – 20 µm were mounted onto Frost +
217 microscope slides and stored at -20°C.

218 **Antibody staining**

219 Mounted sections of tissue were incubated in PBTB (sterile PBS + .01% Tween20 + 0.2% BSA)
220 for 1 hour followed by incubation in 1:500 dilution of primary antibody (Arigo Biolaboratories,
221 Taiwan) for either 1 hour at room temperature or overnight at 4°C. Primary antibody was
222 removed by washing 3X quickly, then 3X for 10 min each in PBTB. Tissue was then incubated
223 in 1:200 dilution of AlexaFluor (546 or 647 – Thermo Fisher Scientific, USA) conjugated
224 secondary antibody in PBTB for 1 hour. Secondary antibody was removed in the same manner as
225 primary antibody, except that DAPI (Thermo Fisher Scientific, USA), and AlexaFluor 488
226 (Thermo Fisher Scientific, USA) conjugated phalloidin was included in the first 10-min wash.
227 Tissue was imaged using an Olympus FV10i confocal microscope.

228 **RNA probe preparation**

229 Target genes were amplified using standard PCR and then cloned into PCRII® Expression vector
230 (Invitrogen, USA) as per the manufacturer's instructions. Cloned products were verified via
231 DNA sequencing and then were linearized by a second PCR using M13F and R primers. After
232 standard PCR cleanup, the linearized gene was quantified and then normalized to 100 ng/µl.

233 Digoxigenin (DIG) tagged probes were made using the SP6 and T7 promoters to make either
234 sense or antisense probes in separate reactions using the following mix: 200 ng linearized cloned
235 PCR product, 2 μ l 10X transcription buffer, 1 μ l of 0.1M DTT (0.02 M DTT for SP6 reaction), 2
236 μ l of DIG labelled ribonucleotides, 1 μ l of RNase inhibitor, 1 μ l of either SP6 or T7 polymerase
237 (New England Biolabs, USA). SP6 reactions were incubated at 40°C for 2 hours, and T7
238 reactions were incubated at 37°C for 1 hour. Successful probe synthesis was confirmed via
239 standard gel electrophoresis, and probes were cleaned using ethanol precipitation and re-
240 suspended in 50 μ l of DEPC H₂O, quantified via spectrophotometry, and stored at -80°C until
241 needed.

242 ***In situ* hybridization**

243 Mounted sections of tissue were incubated in RNase free PBST (sterile PBS + .01% Tween20)
244 for 5 min, 50% PBST: Hybridization buffer (50% formamide, 5X SSC, 100 μ g/ml salmon
245 sperm, 0.1% Tween20, 100 μ g/ml Heparin) for five min, then in hybridization buffer for 5 min.
246 New hybridization buffer was placed on the sections, and pre-hybridization was performed in a
247 small, airtight container at 56°C for 2 hours. The working probe solution was prepared by
248 adding ~200 ng of probe to 100 μ l of hybridization buffer and then incubating at 90°C for 5 min,
249 after which the incubation tubes were placed on ice. The working probe solution was then
250 applied to tissue sections and incubated in an airtight container at 56°C for 16 – 24 hours. Probes
251 were washed from the sections using a variety of wash times and numbers, with all washes using
252 hybridization buffer warmed to 56°C and all washes conducted at 56°C. The following protocol
253 was used to minimize non-specific signal: eight washes of 15 min each, followed by four washes
254 of 30 min each. The slides were then cooled to room temperature and washed 1X for 5 min in
255 50% PBTB: hybridization buffer, 3X for 5 min each in PBTB, 1X for 1 hour in PBTB (to block

256 non-specific protein binding). Slides were then incubated either for 1 hour at room temperature
257 or overnight at 4°C in 1:100 dilution of an HRP conjugated anti-DIG antibody and PBTB. This
258 antibody was removed by three quick washes, and then three 5-min washes in PBTB. Slides
259 were washed in 1X Tyramide buffer for 5 min. Fluorescent labelling was performed using the
260 AlexaFluor Superboost® tyramide signal amplification kit (Thermo Fisher Scientific, USA)
261 following the manufacturer's instructions and using either the 546 or 647 markers. After the
262 tyramide reaction was stopped, excess reagent was removed by washing 3X quickly, then 3X for
263 10 min each in PBTB. DAPI and AlexaFluor 488 conjugated phalloidin were included in the first
264 long wash to label nuclei and cytoskeletal elements, respectively. Tissue was imaged using an
265 Olympus FV10i confocal microscope.

266 **Pathology and NS1 Scoring of Tissues**

267 Brain slices from all animals were prepared, stained, and visualized for detection of NS1 as
268 described above. Tissues were then scored based upon the pathology of the tissue, as well as for
269 expression of NS1. Brain pathology was scored subjectively on a scale of 0-3: 0, normal; 1,
270 mild pathology; 2, moderate pathology; 3, extreme pathology. Brain NS1 levels (extent of
271 fluorescent signal) were scored similarly, using the nuclei visible within the field of view at 60x:
272 0, none; 1, minimal; 2, moderate; 3, extreme. Images from the PBS control animals were used as
273 an example of normal, uninfected tissue, and established a baseline representation score of 0
274 (normal morphology; no NS1 signal).

275

276

277

278 RESULTS

279 Susceptibility of *Monodelphis domestica* to ZIKV infection

280 Viral replication was detected in two of the three animals from Group 1 (2 days old at the time of
281 inoculation), and one of the three animals from Group 2 (3 days old at the time of inoculation).
282 The average titer was 1.8×10^4 PFU/g of brain tissue from the two 2-day old pups in which virus
283 was detected, while the titer from the single 3-day old pup that was infected was 4.3×10^4 PFU/g
284 of brain tissue (Table 1).

285 Table 1 – Zika virus replicates in the brain of newborn *M. domestica* pups

Animals	Animal #1	Animal #2	Animal #3
Group 1 (2-day-old pups)	1.5×10^3 PFU/g	n.d.	2.1×10^4 PFU/g
Group 2 (3-day-old pups)	n.d.	n.d.	4.3×10^4 PFU/g

286
287 Table 1. ZIKV replication following intra-cerebral inoculation of *M. domestica*. Three pups
288 in each of two litters of *M. domestica* were inoculated intra-cerebrally with 5,000 PFU of ZIKV
289 PRVABC59. At 19 days and 23 days post-infection, respectively, animals in the two groups
290 were euthanized, and whole brain was collected, weighed, and homogenized for virus titration in
291 Vero cells. Results are the means of duplicate samples. n.d. = no titer detected.

292

293 Developmental effects of intra-cerebral inoculation

294 One animal (O9355) among the five littermates that were inoculated at 6 days of age and
295 euthanized at 80 days of age had much lower values for body weight, body length, and head
296 length and width, compared to those of its littermates (Fig. 1; Fig. 2). None of the other 10
297 ZIKV-inoculated animals exhibited growth abnormalities. During 40 years of producing nearly
298 150,000 laboratory opossums that were not inoculated with ZIKV, we have not observed another

299 animal with such severe growth restriction, although runts are produced on rare occasions. Also,
300 none of the 10 PBS-inoculated animals exhibited growth restriction.

301 **Presence of viral protein and RNA in brains infected with ZIKV**

302 The brains of the pups were fixed, sectioned, and stained for the presence of ZIKV NS1 protein.
303 Immunofluorescence microscopy showed that, in brains collected from all 16 ZIKV-inoculated
304 animals, anti-ZIKV monoclonal antibody directed against NS1 bound specifically to neuronal
305 cells, indicating that the brains were infected with ZIKV (**Fig. 3a, 3b**). The number of cells
306 visibly expressing NS1 was evaluated and scored based upon the number of nuclei displaying a
307 characteristic punctate staining pattern that we observed in all infected neural tissue samples
308 (**Fig. 1**). All infected animals showed the presence of NS1 within the brain sections, and the
309 amount of signal appeared to correlate to the pathology of the tissue. Animals that showed the
310 most severe pathology also had the highest number of NS1-fluorescing nuclei, while the samples
311 with more moderate and low pathology scores had low to moderate levels of NS1 expression
312 (**Fig. 1**).

313 Spearman's correlation coefficient between these semi-quantitative measures of brain pathology
314 and NS1 signal is 0.59 ($P = 0.008$ for a 1-tailed test of the null hypothesis that there is not a
315 positive correlation between the two measures). Brain tissue sections from each of the 10
316 animals inoculated with PBS exhibited no evidence of ZIKV (**Fig. 3c**). To further confirm the
317 presence of ZIKV replication, an *in-situ* hybridization assay was conducted on brain sections of
318 O9355 to detect ZIKV vRNA using NS5 as a target gene. The results showed a strong signal for
319 ZIKV NS5 RNA in the cerebellum (**Fig. 4**).

320

321 **Pathological consequences of ZIKV infection in the brain**

322 In addition to demonstrating the presence of ZIKV RNA and protein in the brains of infected
323 pups, images of the fixed neural tissues collected from infected opossum pups were also
324 evaluated based upon the observable cell morphology and scored for severity of disease (**Fig. 1**).
325 Most of the brain slices showed either a mild or moderate pathology; however, three samples
326 displayed a discontinuous, spongiform-like pathology with large gaps between cells (i.e., a
327 dramatic reduction in density of cells), along with large clumps of DAPI-stained (blue) DNA,
328 which apparently had been released from cells as they died and which had aggregated into large
329 extra-cellular clumps (**Fig. 5a**). Further examination of brains with this spongiform morphology
330 showed the presence of high levels of ZIKV NS1 protein (**Fig.5b**). The cerebellum slices from
331 the PBS-inoculated control animals had a uniform, contiguous appearance with little to no gaps
332 between cells, no apparent destruction or cell death, and no extracellular DNA (**Fig. 5c-d**).

333 **DISCUSSION**

334 Two critical questions that pertain to development of a new animal model of infection are 1) is
335 the target host organism susceptible to infection and replication of the pathogen, and 2) does the
336 pathology presented in the animal model accurately reproduce at least some of the clinical
337 findings seen in cases of human infection? As mentioned above, flaviviruses such as dengue
338 virus (DENV) and ZIKV grow poorly, or not at all, in non-primate animals with intact immune
339 systems [34]. Indeed, this lack of susceptibility to viral infection has led to the development and
340 use of immunocompromised transgenic mice and chicken embryos as potential models for ZIKV
341 infection [9]. While these models have demonstrated some utility within the context of
342 understanding ZIKV biology, abatement of the primary immune responses directed against
343 viruses for the purpose of establishing infection may hinder the interpretation of results within

344 the context of relevance to human subjects. Normal, wild-type immunocompetent 1-day-old
345 mice (to the limited extent that mice have a competent immune system at that early age) have
346 been used to model aspects of ZIKV replication and pathology [23]; however, 1-day-old mice
347 correlate with a human fetus at 19 weeks of gestation (20 weeks is mid-gestation) [26]. In
348 contrast, a newborn *M. domestica* pup developmentally correlates to a human embryo at 5 weeks
349 of gestation, thus allowing for ZIKV infection in newborn opossum pups to better replicate the
350 pathology in the developing human embryo during the time when cellular differentiation in
351 critical areas such as the brain are at an early stage. Therefore, the laboratory opossum model, in
352 which ZIKV infection at the embryo or early fetal stage can persist long term, and which can be
353 used in large numbers experimentally, is capable of contributing to our understanding of ZIKV-
354 induced pathologies similar to those that are initiated in humans at early developmental stages.

355 Due to the potential severe consequences of ZIKV replication in human brains, and its
356 causal association with neurological diseases such as microcephaly, encephalitis, and Guillain-
357 Barre syndrome [25, 35], the ability of *M. domestica* pups to support viral replication in neuronal
358 tissue is an important first step in the validation of the ZIKV laboratory opossum model. Viral
359 amplification of ZIKV and its long-term persistence following a single intra-cerebral inoculation
360 of 4- to 20-day-old animals demonstrated that: 1) brain cells of this species are permissive to
361 ZIKV replication and, 2) this replication ultimately results in cell death and tissue degradation.
362 The ability of fetal *M. domestica* to support viral infection via the intra-cerebral route is not
363 surprising, as fetal mouse brains also support ZIKV infection [23, 27]. However, the long-term
364 survival and continued replication of ZIKV in the brains of *M. domestica* inoculated as embryos
365 or fetuses was a profoundly different outcome from that which occurs with mice. Analysis of the
366 fixed neural tissue showed the presence of ZIKV NS1 protein diffused throughout the tissue, as

367 well as massive cellular death in the brain compared to age-matched sham-inoculated control
368 animals. The presence of NS1 and its distribution across the cerebellum shows that ZIKV
369 replication was persistent for 74 days beyond the inoculation of the virus and suggests that
370 neuronal cells in varied states of differentiation were exposed to ZIKV. This could explain the
371 global growth restriction we observed for one animal and would be consistent with the selective
372 neuronal vulnerability to ZIKV observed in humans [7]. The NS1 protein of ZIKV is a
373 homodimer that, based upon predicted and known NS1 genetic sequences for other flaviviruses,
374 interacts with a variety of host immune factors [36, 37] and is the major antigenic marker of
375 flavivirus infection [38]. The intracellular form of NS1 is central to viral replication, whereas
376 secreted and membrane bound NS1 have been implicated in the excitation of the immune
377 response [38]. The detection of high levels of ZIKV NS5 RNA 74 days post-infection in the
378 one animal (O9355) examined by in situ hybridization confirms that the presence of NS1
379 detected by immunohistochemistry in the brains of all ZIKV-inoculated pups reflects persistent,
380 active infections in the cerebellum at the time of euthanasia.

381 A critical finding of our study was the correlation between pathology and level of NS1
382 signal in the brains of ZIKV-inoculated pups. We consider the correlation of 0.59 ($P = 0.008$) to
383 be exceptionally high, given that these continuously distributed phenotypes were each
384 subdivided into discrete categories (four for pathology, ranging from 0 to 3; and three for NS1,
385 ranging from 1 to 3, since no ZIKV-inoculated pups scored 0 for presence of NS1). The only
386 three animals that had brains with a spongiform-like pathology (score of 3) all also had the
387 highest score (i.e., 3) for NS1. The only two ZIKV-inoculated pups that had no observable brain
388 pathology (score of 0) had the lowest score for NS1 (i.e., 1) for animals that were inoculated with
389 ZIKV. These results establish that 1) some animals in which ZIKV has been present in their

390 brains since the embryo or fetal stage exhibit no obvious brain pathology, 2) there is variation
391 among littermates in extent of NS1 detected in the brains and consequent extent of pathology, 3)
392 pups as young as 4 days of age and pups as old as 20 days of age at the time of inoculation can
393 develop severe (spongiform-like) brain pathology. Those ages are developmentally equivalent to
394 humans at 8 weeks post conception to 20 weeks post conception (i.e., mid gestation) [26].

395 Another critical finding was the reduction in overall body size of one infected animal
396 compared to its ZIKV-infected littermates or mock-infected control animals. Surprisingly, the
397 brain of the affected animal (O9355) exhibited only mild pathology (score of 1, see Figure 1),
398 suggesting that growth restriction may not be correlated with overall brain pathology, but rather
399 might be a consequence of a localized perturbation in brain development caused by ZIKV
400 infection. While the sample size was small, the physical measurement data suggest that infection
401 of *M. domestica* with ZIKV at the embryonic stage of development can occasionally result in
402 severe growth restriction. Infection of immunocompetent mouse embryos also can result in
403 growth restriction, and it has been suggested that infection of embryonic mouse brain by ZIKV
404 causes an immune response that disrupts neurovascular development [27]. While initial reports
405 from the WHO and CDC originally highlighted microcephaly as the major concern with vertical
406 transmission of ZIKV infection in pregnancy, more recent studies refer to Congenital Zika
407 Syndrome (CZS), of which microcephaly is one severe manifestation of infection. ZIKV
408 infection of a single pregnant pigtail macaque resulted in several sequelae in the fetus
409 reminiscent of CZS in humans, including restricted fetal brain growth and the presence of viral
410 RNA in the brain [14]. Additionally, infection of pregnant rhesus macaques similarly
411 demonstrated evidence of disrupted fetal growth, prolonged maternal viremia, and inflammation
412 at the maternal-fetal interface, including mild decidual perivascular inflammation (not unusual in

413 human decidua) and placental acute chorioamnionitis [39]. Therefore, evaluation of the
414 opossum model using the expanded criteria of CZS (as has been suggested by others to include,
415 but not be limited to, microcephaly), may allow for a more comprehensive understanding of the
416 neurotropism of ZIKV in the fetal brain. In the opossum model, we observed several
417 manifestations of CZS to include: 1) overall reduction in total body size and weight of one
418 animal; 2) the presence of ZIKV NS1 protein as well as NS5 vRNA in the brains of infected
419 pups; and 3) reductions in total number of glial cells, gliosis, hypoplasia, and cellular damage.
420 As discussed above, we also observed a spongiform-like pathology in three infected animals.

421 While it is unknown what the long-term sequelae of CZS would be in the opossum
422 model, studies are underway to evaluate the long-term impact of ZIKV infection on growth,
423 development, mental and physical capabilities, and behavior. Indeed, it has been recently shown
424 that postnatal infection of ZIKV resulted in sustained structural and functional alterations in an
425 infant macaque model [11]. This result suggests that ZIKV infection can have deleterious
426 developmental implications that go far beyond the ‘classical’ definition of ZIKV neuropathology
427 in relation to the size and structure of the brain. Indeed, we have demonstrated that
428 subcutaneous, intramuscular, or intraperitoneal inoculation of ZIKV into juvenile laboratory
429 opossums with intact immune systems can result in chronic infection, viral dissemination to
430 many organs including brain and reproductive organs, and anatomic and histological
431 abnormalities (unpublished data).

432 And, as shown recently, some of the symptoms described in the transgenic murine fetal
433 models do not result in development of microcephaly, suggesting that there may be other factors
434 that influence neurological outcomes in transgenic murine models. For example, studies using

435 pregnant C57BL/6 (Ifnar1^{-/-}) dams infected with ZIKV showed fetal brain damage in the pups;
436 however, no progression to microcephaly was observed [40].

437 The introduction of ZIKV to the Americas has been followed by a steady spread of the
438 virus, tied to the range of the arthropod vector which has also increased in recent years [41].
439 While ZIKV infection rates are certain to rise and fall cyclically, dependent at least in part on
440 weather patterns (particularly rainfall patterns and consequent mosquito density), it is expected
441 that the overall incidence of human infection will increase as more people are exposed to ZIKV
442 via the bites of infected mosquitos. Control methods are currently focused on reduction or
443 elimination of relevant vector populations, including the deployment of genetically modified
444 mosquitos in order to reduce vector populations [42]. In addition, the development and testing
445 of several putative vaccine candidates has also begun [43]. While these techniques probably
446 represent the best-case approach for dealing with ZIKV, the release of genetically modified
447 organisms is a topic that requires intense study and oversight by the FDA before it is approved.
448 Furthermore, the efforts to develop and license a ZIKV vaccine will require at least several more
449 years before such a product could become commercially available. As such, the development
450 and characterization of the major aspects of ZIKV biology, including the neurovirulence and
451 interactions between the immune system and ZIKV, will be required in order to fully support
452 vaccine and drug design. While no animal model may offer a complete, one-stop solution to
453 understanding ZIKV biology, we believe that the *M. domestica* model for studying ZIKV
454 pathogenesis offers unique opportunities to study the effects of CZS in a system that better
455 represents human immunology and pre/post-natal interactions, while allowing for statistically
456 meaningful studies with large numbers of immunocompetent animals.

457 In summary, using the intra-cerebral route of inoculation, we infected *M. domestica* pups
458 at embryonic and early fetal stages of development and, 74 days later, well beyond the age of
459 weaning (56 days), we observed ZIKV replication and consequent pathogenesis in neuronal
460 tissue. One infected animal exhibited a significant retardation in body and head growth. Its four
461 infected littermates appeared to be anatomically normal, as did the other 11 animals that had
462 been inoculated with ZIKV, as well as all 10 animals inoculated with PBS.

463 These data suggest that laboratory opossums can be an important new model for studying
464 the effects of ZIKV replication *in vivo* and perhaps also for testing drug therapies, as well as
465 vaccines and other strategies for preventing pathologies caused by ZIKV infection. Moreover, it
466 is possible that ZIKV persists long-term in the brains of some humans after in utero infection, as
467 it does in opossums, without causing any anatomic developmental abnormalities. Some of the
468 infected opossums also did not exhibit any obvious brain pathologies. Some humans who were
469 infected with ZIKV in utero might continue to harbor ZIKV in their brains (an immunologically
470 privileged site). If they do, some of them might develop brain pathologies as some opossums do,
471 and some of them might not develop brain pathologies. The opossum may prove to be a critical
472 model for research on the long-term effects of in utero ZIKV infection during childhood
473 development and into adulthood.

474 **ACKNOWLEDGEMENTS**

475 We thank Dr. Arthur Porto for directing the work involving head and body measurements, and
476 preparation of heads for photography; Dr. Ana Cristina Leandro for assistance in preparing the
477 photographs of the heads; Dr. Michael Mahaney for advice on statistical analysis; and Alejandro
478 Reyes, Gabriel Lopez, and Cinthya Fuentes-Tapia for expert care of the animals and collection of
479 anatomic data from them.

480

481 **REFERENCES**

- 482 1. Zanoluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K. First report of
483 autochthonous transmission of Zika virus in Brazil. *Memórias do Instituto Oswaldo Cruz*.
484 2015 Jun;110(4):569-72.
485
- 486 2. Sarno M, Sacramento GA, Khouri R, do Rosário MS, Costa F, Archanjo G, Santos LA,
487 Nery Jr N, Vasilakis N, Ko AI, de Almeida AR. Zika virus infection and stillbirths: a case
488 of hydrops fetalis, hydranencephaly and fetal demise. *PLoS neglected tropical diseases*.
489 2016 Feb 25;10(2):e0004517.
490
- 491 3. Hayes EB. Zika virus outside Africa. *Emerging infectious diseases*. 2009 Sep;15(9):1347.
492
- 493 4. Dick GW, Kitchen SF, Haddock AJ. Zika virus (I). Isolations and serological specificity.
494 *Transactions of the royal society of tropical medicine and hygiene*. 1952 Sep
495 1;46(5):509-20.
496
- 497 5. De Carvalho NS, De Carvalho BF, Fugaça CA, Dóris B, Biscaia ES. Zika virus infection
498 during pregnancy and microcephaly occurrence: a review of literature and Brazilian data.
499 *The Brazilian Journal of Infectious Diseases*. 2016 May 1;20(3):282-9.
500
- 501 6. Calvet G, Aguiar RS, Melo AS, Sampaio SA, De Filippis I, Fabri A, Araujo ES, de
502 Sequeira PC, de Mendonça MC, de Oliveira L, Tschoeke DA. Detection and sequencing
503 of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study.
504 *The Lancet infectious diseases*. 2016 Jun 1;16(6):653-60.
505
- 506 7. Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jääskeläinen AJ, Smura T, Rosenberg
507 A, Hill DA, DeBiasi RL, Vezina G, Timofeev J. Zika virus infection with prolonged
508 maternal viremia and fetal brain abnormalities. *New England Journal of Medicine*. 2016
509 Jun 2;374(22):2142-51.
510
- 511 8. Marris C, Olson G, Saade G, Hankins G, Wen T, Patel J, Weaver S. Zika virus and
512 pregnancy: a review of the literature and clinical considerations. *American journal of*
513 *perinatology*. 2016 Jun;33(07):625-39.
514
- 515 9. Pawitwar SS, Dhar S, Tiwari S, Ojha CR, Lapierre J, Martins K, Rodzinski A, Parira T,
516 Paudel I, Li J, Dutta RK. Overview on the current status of Zika virus pathogenesis and
517 animal related research. *Journal of Neuroimmune Pharmacology*. 2017 Sep 1;12(3):371-
518 88.
519
- 520 10. Dudley DM, Aliota MT, Mohr EL, Weiler AM, Lehrer-Brey G, Weisgrau KL, Mohns
521 MS, Breitbach ME, Rasheed MN, Newman CM, Gellerup DD. A rhesus macaque model
522 of Asian-lineage Zika virus infection. *Nature communications*. 2016 Jun 28;7:12204.

- 523 11. Mavigner M, Raper J, Kovacs-Balint Z, Gumber S, O'neal JT, Bhaumik SK, Zhang X,
524 Habib J, Mattingly C, McDonald CE, Avanzato V. Postnatal Zika virus infection is
525 associated with persistent abnormalities in brain structure, function, and behavior in
526 infant macaques. *Science translational medicine*. 2018 Apr 4;10(435):eaao6975.
527
- 528 12. Osuna CE, Lim SY, Deleage C, Griffin BD, Stein D, Schroeder LT, Orange R, Best K,
529 Luo M, Hraber PT, Andersen-Elyard H. Zika viral dynamics and shedding in rhesus and
530 cynomolgus macaques. *Nature medicine*. 2016 Dec;22(12):1448.
531
- 532 13. Waldorf KM, Stencel-Baerenwald JE, Kapur RP, Studholme C, Boldenow E, Vornhagen
533 J, Baldessari A, Dighe MK, Thiel J, Merillat S, Armistead B. Fetal brain lesions after
534 subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. *Nature*
535 *medicine*. 2016 Nov;22(11):1256.
536
- 537 14. Hirsch AJ, Roberts VH, Grigsby PL, Haese N, Schabel MC, Wang X, Lo JO, Liu Z,
538 Kroenke CD, Smith JL, Kelleher M. Zika virus infection in pregnant rhesus macaques
539 causes placental dysfunction and immunopathology. *Nature communications*. 2018 Jan
540 17;9(1):263.
541
- 542 15. Osuna CE, Lim SY, Deleage C, Griffin BD, Stein D, Schroeder LT, Orange R, Best K,
543 Luo M, Hraber PT, Andersen-Elyard H. Zika viral dynamics and shedding in rhesus and
544 cynomolgus macaques. *Nature medicine*. 2016 Dec;22(12):1448.
545
- 546 16. Miner JJ, Sene A, Richner JM, Smith AM, Santeford A, Ban N, Weger-Lucarelli J,
547 Manzella F, Rückert C, Govero J, Noguchi KK. Zika virus infection in mice causes
548 panuveitis with shedding of virus in tears. *Cell reports*. 2016 Sep 20;16(12):3208-18.
549
- 550 17. Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JL, Guimarães KP, Benazzato C,
551 Almeida N, Pignatari GC, Romero S, Polonio CM. The Brazilian Zika virus strain causes
552 birth defects in experimental models. *Nature*. 2016 Jun;534(7606):267.
553
- 554 18. Li C, Xu D, Ye Q, Hong S, Jiang Y, Liu X, Zhang N, Shi L, Qin CF, Xu Z. Zika virus
555 disrupts neural progenitor development and leads to microcephaly in mice. *Cell stem cell*.
556 2016 Jul 7;19(1):120-6.
557
- 558 19. Van den Broek MF, Müller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in
559 mice lacking both alpha/beta and gamma interferon receptors. *Journal of virology*. 1995
560 Aug 1;69(8):4792-6.
561
- 562 20. Deckard DT. Male-to-male sexual transmission of Zika virus—Texas, January 2016.
563 *MMWR. Morbidity and mortality weekly report*. 2016;65.
564

- 565 21. Foy BD, Kobylinski KC, Foy JL, Blitvich BJ, da Rosa AT, Haddock AD, Lanciotti RS,
566 Tesh RB. Probable non-vector-borne transmission of Zika virus, Colorado, USA.
567 Emerging infectious diseases. 2011 May;17(5):880.
568
- 569 22. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to
570 the Th2 pathway in interferon gamma-deficient mice infected with *Leishmania major*.
571 Journal of Experimental Medicine. 1994 Apr 1;179(4):1367-71.
572
- 573 23. Manangeeswaran M, Ireland DD, Verthelyi D. Zika (PRVABC59) infection is associated
574 with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal
575 C57Bl/6 mice. PLoS pathogens. 2016 Nov 17;12(11):e1006004.
576
- 577 24. Brasil P, Pereira Jr JP, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M,
578 Rabello RS, Valderramos SG, Halai UA, Salles TS, Zin AA. Zika virus infection in
579 pregnant women in Rio de Janeiro. New England Journal of Medicine. 2016 Dec
580 15;375(24):2321-34.
581
- 582 25. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—
583 reviewing the evidence for causality. New England Journal of Medicine. 2016 May
584 19;374(20):1981-7.
585
- 586 26. Cardoso-Moreira M, Halbert J, Valloton D, Velten B, Chen C, Shao Y, Liechti A,
587 Ascencao K, Rummel C, Ovchinnikova S, Mazin P. Gene expression across mammalian
588 organ development. Nature. 2019 June 26;571 (504-509).
589
- 590 27. Shao Q, Herrlinger S, Yang SL, Lai F, Moore JM, Brindley MA, Chen JF. Zika virus
591 infection disrupts neurovascular development and results in postnatal microcephaly with
592 brain damage. Development. 2016 Nov 15;143(22):4127-36.
593
- 594 28. VandeBerg JL, Williams-Blangero S. The laboratory opossum. The UFAW Handbook on
595 the Care and Management of Laboratory and Other Research Animals. 2010 Jan
596 19;8:246-61.
597
- 598 29. Samollow PB. The opossum genome: insights and opportunities from an alternative
599 mammal. Genome research. 2008 Aug 1;18(8):1199-215.
600
- 601 30. Wheaton BJ, Noor NM, Dziegielewska KM, Whish S, Saunders NR. Arrested
602 development of the dorsal column following neonatal spinal cord injury in the opossum,
603 *Monodelphis domestica*. Cell and tissue research. 2015 Mar 1;359(3):699-713.
604
- 605 31. Ritter JM, Martines RB, Zaki SR. Zika Virus: Pathology From the Pandemic. Archives
606 of Pathology & Laboratory Medicine. 2017 January 2017; 141(1): 49-59.
607

- 608 32. European Center for Disease Prevention and Control. Rapid Risk Assessment: Zika virus
609 epidemic in the Americas: potential association with microcephaly and Guillain-Barré
610 syndrome. Stockholm: ECDC 2015 Dec 10.
611
- 612 33. Shan C, Xie X, Muruato AE, Rossi SL, Roundy CM, Azar SR, Yang Y, Tesh RB, Bourne
613 N, Barrett AD, Vasilakis N. An infectious cDNA clone of Zika virus to study viral
614 virulence, mosquito transmission, and antiviral inhibitors. *Cell host & microbe*. 2016 Jun
615 8;19(6):891-900.
616
- 617 34. Elong Ngono A, Shresta S. Immune response to dengue and Zika. *Annual review of*
618 *immunology*. 2018 Apr 26;36:279-308.
619
- 620 35. Schuler-Faccini L. Possible association between Zika virus infection and microcephaly—
621 Brazil, 2015. *MMWR. Morbidity and mortality weekly report*. 2016;65.
622
- 623 36. Song H, Qi J, Haywood J, Shi Y, Gao GF. Zika virus NS1 structure reveals diversity of
624 electrostatic surfaces among flaviviruses. *Nature structural & molecular biology*. 2016
625 May;23(5):456.
626
- 627 37. Winkler G, Randolph VB, Cleaves GR, Ryan TE, Stollar V. Evidence that the mature
628 form of the flavivirus nonstructural protein NS1 is a dimer. *Virology*. 1988 Jan
629 1;162(1):187-96.
630
- 631 38. Young PR, Hilditch PA, Bletchly C, Halloran W. An antigen capture enzyme-linked
632 immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of
633 infected patients. *Journal of clinical microbiology*. 2000 Mar 1;38(3):1053-7..
634
- 635 39. Nguyen SM, Antony KM, Dudley DM, Kohn S, Simmons HA, Wolfe B, Salamat MS,
636 Teixeira LB, Wiepz GJ, Thoong TH, Aliota MT. Highly efficient maternal-fetal Zika
637 virus transmission in pregnant rhesus macaques. *PLoS pathogens*. 2017 May
638 25;13(5):e1006378.
639
- 640 40. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, Diamond MS. A
641 mouse model of Zika virus pathogenesis. *Cell host & microbe*. 2016 May 11;19(5):720-
642 30.
643
- 644 41. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, Moore CG,
645 Carvalho RG, Coelho GE, Van Bortel W, Hendrickx G. The global distribution of the
646 arbovirus vectors *Aedes aegypti* and *Ae. albopictus*. *elife*. 2015 Jun 30;4:e08347.
647
- 648 42. Alphey L, Benedict M, Bellini R, Clark GG, Dame DA, Service MW, Dobson SL.
649 Sterile-insect methods for control of mosquito-borne diseases: an analysis. *Vector-Borne*
650 *and Zoonotic Diseases*. 2010 Apr 1;10(3):295-311.

651 43. Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL, Kalil J. Development of
652 vaccines against Zika virus. *The Lancet Infectious Diseases*. 2018 Jul 1;18(7):e211-9.

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680 **FIGURES AND DATA**

681 **Figure 1**


Litter Number	Breeding Stock	ID Number	Sex	Inoculation Age (Days after Birth)	Equivalent Human Age (Wks. Post-conception)	Inoc. Vol. (µL)	Virus or PBS	Age at Harvest	Animal Weight (g)	Nose-Rump Length (mm)	Head Length (mm)	Head Width (mm)	Pathology	NS1
1	PBP	O9378	F	4	8	2	V	78	48.3	117.7	35.6	17.6	3	3
	PBP	O9379	F	4	8	2	V	78	48.6	116.2	34.2	17.6	0	1
	PBP	O9380	M	4	8	2	V	78	59.1	123.0	36.9	18.5	1	2
	PBP	O9381	M	4	8	2	V	78	56.8	117.4	35.9	18.4	3	3
2	LL1	O9355	F	6	12	2	V	80	16.7	74.7	27.0	14.2	1	2
	LL1	O9356	F	6	12	2	V	80	48.6	114.8	35.5	18.3	1	3
	LL1	O9357	F	6	12	2	V	80	39.6	109.8	35.6	16.7	2	3
	LL1	O9358	F	6	12	2	V	80	40.4	109.6	33.5	17.3	1	3
	LL1	O9359	M	6	12	2	V	80	47.7	117.0	36.3	19.0	1	2
	FD2M	O9335	F	9	12.5	5	V	83	39.7	112.8	35.5	17.6	0	1
3	FD2M	O9336	M	9	12.5	5	V	83	38.3	106.6	34.5	17.1	2	2
	FD2M	O9337	M	9	12.5	5	V	83	41.7	112.5	36.0	16.9	1	3
	LL1	O9248	F	20	20	10	V	94	52.4	124.3	38.0	18.4	1	3
4	LL1	O9249	M	20	20	10	V	94	72.8	134.9	40.4	19.2	1	2
	LL1	O9250	M	20	20	10	V	94	55.2	123.3	39.4	17.9	1	3
	LL1	O9251	M	20	20	10	V	94	66.0	132.0	40.1	19.2	3	3
	ATHHN	O9394	F	2	7	1	PBS	76	32.1	98.6	31.9	17.0	0	0
5	ATHHN	O9395	M	2	7	1	PBS	76	29.8	98.0	31.8	16.8	0	0
	ATHHN	O9396	M	2	7	1	PBS	76	34.6	102.5	33.0	16.3	0	0
	ATHHN	O9382	F	4	8	2	PBS	78	28.4	96.6	30.3	16.8	0	0
	ATHHN	O9383	M	4	8	2	PBS	78	22.9	88.5	28.4	15.0	0	0
	ATHHN	O9384	M	4	8	2	PBS	78	27.9	96.0	31.3	15.5	0	0
	ATHHN	O9385	M	4	8	2	PBS	78	36.2	102.4	31.5	17.1	0	0
	LSD	O9339	F	9	12.5	5	PBS	83	32.8	99.4	29.6	16.8	0	0
6	LSD	O9340	F	9	12.5	5	PBS	83	34.4	99.9	32.8	15.8	0	0
	LSD	O9341	M	9	12.5	5	PBS	83	33.6	100.4	31.2	16.9	0	0

682

683 **Figure 1. Weights, anatomic measurements, and brain scores from ZIKV-inoculated and**
 684 **PBS-inoculated laboratory opossum pups.** Note that weights and measurements among litters
 685 are not comparable, because of different ages of harvest and differences among breeding stocks
 686 in growth rates. Brain pathology was scored subjectively on a scale of 0-3: 0, normal; 1, mild
 687 pathology; 2, moderate pathology; 3, extreme pathology (spongiform-like appearance). Brain
 688 NS1 levels (extent of fluorescent signal) were scored similarly: 0, none; 1, minimal; 2,
 689 moderate; 3, extreme.


690

691 **Figure 2**



700 **Figure 2. Heads of normal (top) and growth restricted (bottom) *M. domestica* littermates at**
701 **80 days of age. 6-day-old *M. domestica* pups from a single litter were inoculated with 5,000**
702 **PFU of ZIKV PRVABC59 intra-cerebrally. At 74 days post-infection (80 days of age), the**
703 **animals were euthanized, and photographs and measurements (Fig. 1) of the heads were taken.**

704 **Figure 3**




707 **Figure 3. Immunohistochemical detection of ZIKV. (a) Immunofluorescence staining of**
708 **transverse section of cerebellum from infected growth-restricted pup (O9355) at 60x with anti-**
709 **ZIKV NS1 monoclonal antibody (red). Cytoskeleton is stained green; nuclei are blue. (b)**
710 **Cerebellum section from an infected littermate (O9357). (c) Cerebellum section from a mock-**
711 **infected animal (O9341) at 60x.**

712

713

714

715 **Figure 4**




716

717 **Figure 4. *In-situ* hybridization detection of ZIKV RNA.** Immunofluorescence staining of
718 transverse section of cerebellum from infected growth-restricted pup (O9355) at 60x showing the
719 presence of ZIKV NS5 mRNA (red): nuclei are blue.

720

721 **Figure 5**

722



723

724 **Figure 5. Spongiform morphology induced by ZIKV infection.** (a) Immunofluorescence
725 staining of transverse section of cerebellum from an infected pup (O9251) at 10x showing a
726 spongiform-like pathology in the presence of ZIKV NS1 protein (red). Cytoskeleton is stained
727 green; nuclei are blue. (b) Cerebellum from the same animal at 60x. (c) Cerebellum from a
728 mock-infected animal (O9339) at 10x. (d) Cerebellum from the same mock-infected animal
729 (O9339) at 60x.

730


Figure 1

Litter Number	Breeding Stock	ID Number	Sex	Inoculation Age (Days after Birth)	Equivalent Human Age (Wks. Post-conception)	Inoc. Vol. (µL)	Virus or PBS	Age at Harvest	Animal Weight (g)	Nose-Rump Length (mm)	Head Length (mm)	Head Width (mm)	Pathology	NS1
1	PBP	O9378	F	4	8	2	V	78	48.3	117.7	35.6	17.6	3	3
	PBP	O9379	F	4	8	2	V	78	48.6	116.2	34.2	17.6	0	1
	PBP	O9380	M	4	8	2	V	78	59.1	123.0	36.9	18.5	1	2
	PBP	O9381	M	4	8	2	V	78	56.8	117.4	35.9	18.4	3	3
2	LL1	O9355	F	6	12	2	V	80	16.7	74.7	27.0	14.2	1	2
	LL1	O9356	F	6	12	2	V	80	48.6	114.8	35.5	18.3	1	3
	LL1	O9357	F	6	12	2	V	80	39.6	109.8	35.6	16.7	2	3
	LL1	O9358	F	6	12	2	V	80	40.4	109.6	33.5	17.3	1	3
	LL1	O9359	M	6	12	2	V	80	47.7	117.0	36.3	19.0	1	2
	FD2M	O9336	M	9	12.5	5	V	83	38.3	106.6	34.5	17.1	2	2
4	LL1	O9248	F	20	20	10	V	94	52.4	124.3	38.0	18.4	1	3
	LL1	O9249	M	20	20	10	V	94	72.8	134.9	40.4	19.2	1	2
	LL1	O9250	M	20	20	10	V	94	55.2	123.3	39.4	17.9	1	3
	LL1	O9251	M	20	20	10	V	94	66.0	132.0	40.1	19.2	3	3
	ATHHN	O9394	F	2	7	1	PBS	76	32.1	98.6	31.9	17.0	0	0
5	ATHHN	O9395	M	2	7	1	PBS	76	29.8	98.0	31.8	16.8	0	0
	ATHHN	O9396	M	2	7	1	PBS	76	34.6	102.5	33.0	16.3	0	0
	ATHHN	O9382	F	4	8	2	PBS	78	28.4	96.6	30.3	16.8	0	0
	ATHHN	O9383	M	4	8	2	PBS	78	22.9	88.5	28.4	15.0	0	0
	ATHHN	O9384	M	4	8	2	PBS	78	27.9	96.0	31.3	15.5	0	0
	ATHHN	O9385	M	4	8	2	PBS	78	36.2	102.4	31.5	17.1	0	0
	LSD	O9339	F	9	12.5	5	PBS	83	32.8	99.4	29.6	16.8	0	0
6	LSD	O9340	F	9	12.5	5	PBS	83	34.4	99.9	32.8	15.8	0	0
	LSD	O9341	M	9	12.5	5	PBS	83	33.6	100.4	31.2	16.9	0	0

bioRxiv preprint doi: <https://doi.org/10.1101/785220>; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 1. Weights, anatomic measurements, and brain scores from ZIKV-inoculated and PBS-inoculated laboratory opossum pups. Note that weights and measurements among litters are not comparable, because of different ages of harvest and differences among breeding stocks in growth rates. Brain pathology was scored subjectively on a scale of 0-3: 0, normal; 1, mild pathology; 2, moderate pathology; 3, extreme pathology (spongiform-like appearance). Brain NS1 levels (extent of fluorescent signal) were scored similarly: 0, none; 1, minimal; 2, moderate; 3, extreme.


Figure 2



bioRxiv preprint doi: <https://doi.org/10.1101/785220>; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 2. Heads of normal (top) and growth restricted (bottom) *M. domestica* littermates at 80 days of age. 6-day-old *M. domestica* pups from a single litter were inoculated with 5,000 PFU of ZIKV PRVABC59 intra-cerebrally. At 74 days post-infection (80 days of age), the animals were euthanized, and photographs and measurements (**Fig. 1**) of the heads were taken.

Figure 3



bioRxiv preprint doi: <https://doi.org/10.1101/785329>; this version posted September 27, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 3. Immunohistochemical detection of ZIKV. (a) Immunofluorescence staining of transverse section of cerebellum from infected growth-restricted pup (O9355) at 60x with anti-ZIKV NS1 monoclonal antibody (red). Cytoskeleton is stained green; nuclei are blue. **(b)** Cerebellum section from an infected littermate (O9357). **(c)** Cerebellum section from a mock-infected animal (O9341) at 60x.

Figure 4





Figure 4. *In-situ* hybridization detection of ZIKV RNA. Immunofluorescence staining of transverse section of ceratohaline from infected pup (O9355) at 60x showing the presence of ZIKV NS5 mRNA (red); nuclei are blue.

bioRxiv preprint doi: <https://doi.org/10.1101/170570>; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 5



bioRxiv preprint doi: <https://doi.org/10.1101/785220>; this version posted September 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Figure 5. Spongiform morphology induced by ZIKV infection. (a) Immunofluorescence staining of transverse section of cerebellum from an infected pup (O9251) at 10x showing a spongiform-like pathology in the presence of ZIKV NS1 protein (red). Cytoskeleton is stained green; nuclei are blue. (b) Cerebellum from the same animal at 60x. (c) Cerebellum from a mock-infected animal (O9339) at 10x. (d) Cerebellum from the same mock-infected animal (O9339) at 60x.